Greetings, and welcome to the Tenon Medical Third Quarter 2025 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steven Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the third quarter ended 09/30/2025 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website. Before we begin the formal presentation, I'd like to remind everyone that statements made on the call and webcast may include predictions, estimates, and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind, we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission.

Thank you, and good afternoon, everyone. I'm pleased to welcome you to today's Third Quarter 2025 Financial Results and Corporate Update Conference Call for Tenon Medical. The third quarter was a very exciting time for Tenon Medical, where our progress is really showing through in our financial results. Our results demonstrate significant momentum in executing our strategic growth initiatives. We achieved record revenue of $1,200,000 with a 32% increase compared to the same period last year. This performance was fueled by unprecedented cadmium procedure volumes, underscoring strong demand and growing adoption among physicians. Additionally, the integration of the SciVantage portfolio contributed meaningfully to our top-line growth, an early indication of what our portfolio expansion strategy can deliver. These results affirm the strength of our commercial and the increasing recognition of our differentiated solutions in the marketplace. As discussed during our second quarter earnings conference call, and in line with our commitment to advancing innovation and expanding our market presence, we completed a strategic asset acquisition of CyVantage's Symmetry and Symmetry Plus sacroiliac joint fusion technologies during the third quarter. This transaction marks a pivotal milestone in our growth strategy, transforming Tenon into a multiproduct, multiproduct company capable of addressing a broader spectrum of sacropelvic fixation infusion needs. The Symmetry platform brings a well-established clinical foundation and a differentiated approach to fusion, complementing our existing cadmium system. Importantly, this acquisition has been immediately accretive to revenue and enhances our ability to serve a wider range of physicians and patients. We also welcome key members of the CyVantage leadership team whose deep experience and expertise will be instrumental in accelerating our commercial execution and driving continued innovation. I'd like to quickly acknowledge the efforts of the newly combined team for efficiently coming together as one, aggressively completing integration activities, and delivering a strong quarter. Another key milestone this quarter was the full commercial launch of our Catamaran SE, SI joint fusion system, which expands our implant portfolio and strengthens our competitive position in the sacroiliac joint fusion market. The Catamaran SE features a reduced profile, offering physicians greater flexibility when treating patients with smaller SI joint anatomy or performing revision procedures. This design enhancement supports a minimally invasive inferior posterior approach and includes a proprietary instrument set with multiple drilling options catering to diverse surgical preferences. Backed by expanded inventories and field support, bolstered by our recent SciVantage acquisition, we are well-positioned to meet growing market demand. With over a thousand catamaran devices implanted to date, the system continues to demonstrate strong clinical performance across a range of indications, including primary SI joint dysfunction, revision, and adjunctive applications in complex multilevel spine fusions. The successful transition from alpha testing to full launch reflects our commitment to innovation and our ability to execute with speed and precision. During the quarter, we were proud to share that the second peer-reviewed publication from our ongoing main sales study was published. This further validated the safety, efficacy, and durability of the Catamaran SI joint fusion system. This prospective multicenter clinical trial evaluated patient outcomes in patients with sacroiliac joint disruptions, degenerative sacroiliac treated with our catamaran implant. The twelve-month data from the first twenty-four patients demonstrated statistically significant improvements in pain and disability scores. VAS scores dropped from 78.8 preoperatively to 23 postoperatively, and ODI scores improved from 51.6% to 20.8%. Notably, eighty-three percent of patients showed unequivocal evidence of fusion with bridging bone across the SI joint at twelve-month CT confirmed by independent radiographic review. The study also reported no serious adverse events, reoperations, or reinfections, and eighty-three percent of patients expressed high satisfaction with their outcomes. These results reinforce the Catamaran system's clinical value and support its role as a reliable, minimally invasive solution for SI joint dysfunction. As we continue to build our clinical evidence base, we believe these findings will be instrumental in driving broader adoption and payer coverage that supports our long-term growth. Subsequent to quarter end, we announced a major regulatory milestone with the FDA 510(k) clearance of our Symmetry Plus SI joint fusion system. This next-generation platform builds on the proven foundation of the original Symmetry system and introduces several key advancements, including 3D printed titanium implants, a robust joint decorticator, and a simplified bone graft delivery system. These enhancements are designed to support authentic arthrodesis through a minimally invasive lateral approach, rooted in established orthopedic fusion principles. With this clearance, Tenon now offers two distinct minimally invasive surgical approaches: an inferior posterior through our Symmetry Plus and Catamaran systems, respectively. This multiplatform strategy significantly strengthens our competitive position and enables physicians to tailor treatment to individual patient anatomy and pathology. We are prepared for an alpha launch of Symmetry Plus in the coming weeks. A select group of physician users whose feedback will guide our broader market introduction will be the first to use the technology. This milestone not only expands our portfolio but also reinforces our commitment to delivering durable, clinically validated outcomes for patients suffering from sacroiliac joint dysfunction. Physician education remains a top priority. In the third quarter, we hosted 26 physicians in various Tenon workshops, including critical peer-to-peer engagements. We ended the quarter with $3,400,000 in cash and no debt. Subsequent to quarter end, we bolstered our cash position with a $2,850,000 financing primarily consisting of investments from industry partners, giving us the flexibility to continue executing our strategic roadmap with confidence. Looking ahead, we remain focused on driving adoption across our expanded product portfolio and leveraging recent regulatory and clinical milestones to support commercial growth. With a strong foundation in place, we are confident in our ability to scale up operations, deepen market penetration, and deliver continued value in the quarters to come. We are actively onboarding sales professionals to the Tenon commercial team through a strategic hybrid structure, and we're already seeing the momentum build into the fourth quarter, driven by the expansion of our commercial footprint and increased horsepower of our sales organization. And with that, I'll turn the call over to Kevin to discuss our financials in detail.

Thank you, Steve. I will now provide a summarized review of our financial results. A full breakdown is available in our press release that crossed the wire this afternoon. Revenue for 2025 was $1,200,000, an increase of 32.3% compared to $900,000 in the same period last year. Revenue for the nine months ended 09/30/2025 was $2,500,000, in line with $2,500,000 for the nine months ended 09/30/2024. The increase in the third quarter revenue was primarily driven by an increase in the number of surgical procedures in which the catamaran system was used, as well as the addition of sales in the last two months of the quarter from the newly acquired Symmetry SI joint fusion system. The demand for both Catamaran and Symmetry increased throughout the quarter and has continued into the fourth quarter. Gross profit was $800,000 or 66% of revenue in 2025, compared to $400,000 or 47% in the prior year quarter. For the nine months ended 09/30/2025, gross profit was $1,300,000 or 54% of revenue, compared to $1,400,000 or 54% of revenue for the previous year's period. Gross margin for the quarter improved due to higher revenue absorbing fixed overhead costs in our cost of goods sold. With a similar margin profile for both Symmetry and Catamaran, we expect our gross margin to continue to improve as revenue increases and fixed overhead costs are further absorbed. Operating expenses totaled $4,200,000 in 2025, up from $3,600,000 in the prior year period. For the nine months ended 09/30/2025, operating expenses totaled $11,300,000, compared to $12,000,000 in the prior year period. The increase in operating expenses for the quarter was primarily due to higher sales expenses driven by higher revenue and related variable commission expenses, as well as higher marketing and G&A expenses driven by integration efforts in relation to the SciVantage acquisition. The decrease in operating expenses in the nine months was driven by lower fixed expenses, including lower stock-based compensation across several operating categories. Net loss for the third quarter was $3,300,000 or $0.40 per share, compared to a net loss of $3,200,000 or $3.63 per share in 2024. For the nine months ended 09/30/2025, net loss was $9,700,000, compared to $10,600,000 in the same year-ago period. The year-over-year improvement was largely driven by reduced operating expenses and lower fixed costs, raising operational leverage. We ended the quarter with $3,400,000 in cash and cash equivalents, compared to $6,500,000 as of 12/31/2024. Subsequent to quarter end, Tenon raised an additional $2,850,000 in cash to fund future growth initiatives through financing. The financing was led by an industry-supported investor cohort that believes in the strategic vision of Tenon and the growth opportunity in front of us. Additionally, Tenon had no outstanding debt as of quarter end, further positioning the company to continue executing on our strategic initiatives, including the development and launch of the SciVantage assets, continuing to build clinical evidence, and expanding our commercial footprint. In summary, we believe the transformational steps taken this quarter, both financially and strategically, position Tenon well to accelerate growth while maintaining a lean and focused cost structure and driving long-term shareholder value. I'll now hand the call back to Steve for closing comments.

Thank you, Kevin. In summary, the third quarter was marked by strong execution across our strategic priorities, from record revenue growth and the successful integration of the SciVantage acquisition to the full market launch of Catamaran SE and key regulatory and clinical milestones. We remain focused on expanding our portfolio, deepening physician engagement, and building a robust foundation for sustained growth. With momentum building across our commercial and clinical initiatives, we are confident in our ability to drive long-term value for patients, providers, and shareholders. I thank you all for attending, and I'd like to hand the call back over to our operator to begin the question and answer session with our covering analysts.

Thank you. At this time, we'll be conducting a question and answer session. If you'd like to ask a question, please press 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question comes from Scott Henry with AGP. Please proceed with your question.

Thank you, and good afternoon. It's exciting to see the company come together as it approaches greater scale. A couple of questions. First, could you comment on the product revenues, how much was the kind of base CyVantage revenues of the $1,200,000?

Thank you, Scott. I appreciate the question. Yes. So we're obviously early. We had two months of CyVantage product contribution, if you will, to the top line in the third quarter. We closed right around August 1. The transaction itself. So primarily, the primary driver of our revenue was record catamaran procedures and what have you. We did a little over a million, close to a million one in catamaran revenue. And the rest of the revenue was early Symmetry activity. Keep in mind that the Symmetry activity is base what I refer to as base Symmetry technology. We're just now in the coming week or two going to initiate the Symmetry Plus Alpha. So start seeing revenue build from Symmetry Plus here going forward.

Okay. Great. And, you know, obviously, sequentially in the fourth quarter, you'll get another month of the base CyVantage revenues. You'll get the Symmetry Plus contribution even if it's small at that point. But would you expect Catamaran to grow sequentially from third quarter 2025 to fourth quarter 2025?

We do. I think, you know, look. The drivers behind Catamaran is data. You know, the main sale data continuing to come out and show that Catamaran is delivering on its promises. So we do expect Catamaran activity, number of surgical procedures, etc. to continue to grow. And to your point, you know, we'll get the extra month of CyVantage activity in the full fourth quarter. And, frankly, what means more to us is this initial phase of the alpha launch of Symmetry Plus. We have physicians who are really excited about getting their hands on that technology. We anticipate it'll be a good growth driver as we move through alpha.

Okay. Great. And when we think about the Symmetry Plus Alpha launch, you know, how should I think about that? Should I think of that as a pilot launch at first, or is that a full-scale launch? Just trying to get a sense of how that launch will evolve, you know, over the next six to twelve months.

Yeah. I appreciate that question. Absolutely. It's the physicians that informed us and partnered with us to give us feedback on what they wanted the system to do, etc. will be the first users of the technology. So it's a relatively small and focused group in the first, call it, sixty to ninety days of the alpha. Then we get feedback and make absolutely sure, hey, is everything working as expected? Are refinements required? Are there tweaks required? Etc. to make sure this is ready for prime time, if you will, and to go to a broader audience. And at that point, we'll start expanding things pretty aggressively. So it's exactly what you said. Right? It's a bit of a pilot, if you will, for a short period of time to make sure we got everything right. And that the instruments and the implants are meeting expectations.

Okay. Great. And just the final question, perhaps for Kevin. G&A, do you think the third quarter is reflective of what we'll start to see on a quarterly basis? Or I know you'll have another month of, should we be thinking about, you know, CyVantage, but, you know, it looks like maybe there were some one-time stuff in there as well. Is it $2,100,000 to $2,200,000 a quarter?

Yes. Good question, Scott. Fair on both of your comments. So, a little bit of some one-time more integration type expenses in there. But also some increased expenses going forward. So, you know, probably somewhere just south of that number we posted here in Q3. But closer to that number than where we were previously, given some of the increased expenses going forward.

Okay. Great. Thank you for that color. And thank you guys for taking the questions.

Thank you, Scott. Please press 1 on your telephone keypad. One moment, please, while we poll for questions. Our next question comes from Thomas McGovern with Maxim Group. Please proceed with your question.

Thank you. So it sounds like you guys are well on your way to integrating CyVantage. I just want to get maybe an update on how that process is going. Is it fully done? Are there additional milestones you're looking to achieve in this integration process? Maybe just kind of high level how you view it moving into the fourth quarter.

Yeah. Thanks for the question, Thomas. Yeah. Look. I'm really, really proud. I mentioned it in the prepared statements here, and we'll reinforce it here. Live through a lot of integrations. Bringing people together and getting them to, if you will, take the risk to dive in, to trust each other, to get after it, and start performing as one is really the biggest challenge in these integrations. Right? And I'm just really, really pleased with the progress that we've made. Sure. There's all kinds of stuff to do with the audit itself. You know, just some of the tactical stuff that has to be done as part of an integration. It's really about winning hearts and minds. And this team is coming together really nicely as one and starting to check all the boxes so we can perform as an integrated team going forward. So just super, super proud of the work that's being done. Kevin can comment a little bit, but I think largely, we are finished now. And a good indicator of that, probably the best indicator of that, is bringing the Symmetry Plus Alpha in on time and executing on that in the course of all of the integration activities going on. You know, we'll initiate that here this month. And we're super excited about seeing what Symmetry Plus can do out there with physicians that prefer a lateral approach. So all of those things are coming together, Thomas. And I'm just really thankful to the CyVantage folks, the Tenon folks coming together and becoming the new Tenon. It really has been a pleasure to work with everybody.

Great. I appreciate that answer.

Apologies there. I can just quickly add, you know, to keep in mind this even though this was a business combination, we really acquired just the assets of CyVantage. So integrating the assets, the inventories, the know-how into our quality system and into our commercial team was really the main focus. Obviously, a focus on launching Symmetry Plus as we acquired those products right before this launch coming up here in the coming weeks. And then integrating the customer base, the physician base, distributor base to continue and accelerate sales. So I think we feel very good about how that played out throughout the quarter and how we're rolling up here so far in Q4.

Great. Glad to hear it. And, again, thank you guys for answering that. Next question for me. You guys mentioned adding commercial sales professionals. So just curious if you could maybe quantify, just give us an idea of the scope of these headcount additions. And then maybe a little bit more on kind of how you guys plan to balance marketing for Catamaran versus CyVantage and Symmetry Plus. You know, are there going to be specialized salespeople for specific products? Are these going to be cross-trained salespeople? Just kind of give us an idea of your strategy as you move forward.

Excellent. Yeah. So first to the scope of commercial additions. Right? So one of the many upsides to the CyVantage activity in the transaction that we did is onboarding some really key commercial members, Nate Rowe, White Geist, really experienced people that come on board that have an entire network of relationships through their years of experience, etc., it's going to greatly enhance what we're doing out there. We're committed to a hybrid commercial structure, meaning we'll be engaging independent distributors and ten ninety-nine resources. And that'll be managed by our direct sales management team led by Nate Growe as our chief commercial officer. So, we'd see the scope of that continuing to grow really quickly. Onboarding these distributors and getting them trained, etc. To your second question, these folks will be informed and trained across Tenon and all of our products in the portfolio. Right? What we want to be able to do is present ourselves to a physician as having a tool bag that will allow them to choose what they prefer in treating patients with these sacropelvic disorders. Right? They prefer lateral approaches. We want to have the state-of-the-art solution for what they're looking for. If they prefer an inferior posterior approach, we have that with Catamaran, etc. And what we rally around, Thomas, are the principles of an authentic fusion. Right? You'll see all of these products check the boxes of AO principles of arthrodesis. Right? We don't dance around that topic. We don't just put a screw in and say there. These are technologies, surgical techniques, and instruments that deliver across those requirements. So the distributors that we're interfacing with rally around those principles. And they will be trained on all aspects of what Tenon has to offer.

Understood. I appreciate the thorough response there. And last thing for me, you know, you guys highlighted again your clinical data. Obviously, you know, great in terms of not only, you know, educating physicians but also pursuing additional payer coverage decisions. So just curious, you know, maybe how are you weighting that as you're looking at several commercial ramp-ups, the commercial pilot program or the pilot launch, if you will, of Symmetry Plus. How are you balancing, you know, your focus on that expanding headcount and integration along with using this data to pursue, you know, additional payer coverage? Just kind of want to understand how you're stacking your priorities maybe in the next several months.

Yeah. Sure. So, you know, priorities were more strategic in the last two to three years as it related to, you know, engaging the process and making sure coding big picture coding issues were addressed. And that codes became clear so that, you know, things could be done accurately out in the field. That's fantastic. But you have a medical device technology. It has to be backed by prospective data in order for it to be accepted in most cases and covered by the private payers in particular. And so we're in that stage now with the publication of the catamaran data with the data that the dataset that's in place for symmetry technology, we can have a very, very thorough discussion with private payers and commercial payers and make sure these technologies are recognized and covered within their policies. So there's a great deal of work going on there. You know, it's not the fastest work in the world. I wish it was, but it's not. But working through all of that takes time and effort from a focused group. But that's a separate group from our commercial organization. Our commercial organization is really focused on engaging physicians, providing world-class training opportunities for them so they can be fully informed. World-class peer-to-peer opportunities so they can learn from physicians who have adopted these technologies, etc. That's really a separate set of activities, Thomas. And so, really, we're doing those things, you know, in parallel out there and really one's not prioritized over the other. They're both equally important and exceedingly important to drive our opportunities to grow going forward.

Got it. Well, thanks for answering all my questions, and congrats on the quarter, I guess.

Thanks, Thomas.

We have reached the end of the question and answer session. I'd now like to turn the call back over to Steven Foster for closing comments.

Thank you. I'd like to thank each of you for joining our earnings conference call today. We look forward to continuing to update you on our ongoing progress. And if for some reason we were unable to answer any of your questions, please reach out to our IR firm, who'll be more than happy to assist. And with that, I wish everybody a good evening.

This concludes today's conference. You may disconnect your lines at this time. And we thank you for your participation.